BibSonomy :: user :: kanefendt

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome

E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom. Ann.Oncol. 18(10):1745-1747 (2007)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

C. Kut, Gabhann F. Mac, and A. S. Popel. Br.J.Cancer 97(7):978-985 (2007)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Molecular mechanisms of lymphatic vascular development

T. Makinen, C. Norrmen, and T. V. Petrova. Cell Mol.Life Sci. 64(15):1915-1929 (2007)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel. Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)

3 years and 3 months ago

by kanefendt

1

& A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity

(0)

URLDOITeX

Molecular basis for sunitinib efficacy and future clinical development

S. Faivre, G. Demetri, W. Sargent, and E. Raymond. Nat.Rev.Drug Discov. 6(9):734-745 (2007)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen

J. L. Duque, K. R. Loughlin, R. M. Adam, P. Kantoff, E. Mazzucchi, and M. R. Freeman. Clinics. 61(5):401-408 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a review

F. A. Eskens, and J. Verweij. Eur.J.Cancer 42(18):3127-3139 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment

A. Gampel, L. Moss, M. C. Jones, V. Brunton, J. C. Norman, and H. Mellor. Blood 108(8):2624-2631 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions

A. Morabito, Maio E. De, Maio M. Di, N. Normanno, and F. Perrone. Oncologist. 11(7):753-764 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients

S. Nadar, A. D. Blann, and G. Y. Lip. Am.J.Hypertens. 19(9):970-977 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis

M. Shibuya. J Biochem.Mol.Biol. 39(5):469-478 (2006)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

H. M. Verheul, and H. M. Pinedo. Nat.Rev.Cancer 7(6):475-485 (2007)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, G. Dicuonzo, L. Rocci, V. M. Rosaria, N. Gebbia, and G. Tonini. Pharmacogenomics. 8(4):319-327 (2007)

3 years and 3 months ago

by kanefendt

1

& A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use

(0)

URLDOITeX

Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

M. J. Cuadrado, P. Buendia, F. Velasco, M. A. Aguirre, N. Barbarroja, L. A. Torres, M. Khamashta, and C. Lopez-Pedrera. J.Thromb.Haemost. 4(11):2461-2469 (2006)

3 years and 3 months ago

by kanefendt

1

& A Adolescent Adult Aged Antibodies Antiphospholipid Cells Cultured Endothelial Enzyme Expression Factor Female Gene Growth Human Humans Imidazoles Inhibitors Kinase Kinases MAP Male Middle Mitogen-Activated Monocytes Phenotype Protein Pyridines Receptor-1 Regulation Research Signaling Syndrome System Thromboplastin Thrombosis Tyrosine Vascular antagonists biosynthesis cells drug effects inhibitors metabolism p38 pathology pharmacology protein

(0)

URLDOITeX

A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap

F. T. Wu, M. O. Stefanini, Gabhann F. Mac, and A. S. Popel. PLoS.One. 4(4):e5108 (2009)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Soluble angiogenesis markers in gastric tumor patients

P. Mysliwiec, K. Pawlak, R. Bandurski, and B. Kedra. Folia Histochem.Cytobiol. 47(1):81-86 (2009)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

How well do angiogenesis inhibitors work? Biomarkers of response prove elusive

V. Brower. J.Natl.Cancer Inst. 101(12):846-847 (2009)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Angiogenesis induced by hVEGF165 gene controlled by hypoxic response elements in rabbit ischemia myocardium

H. Dong, Q. Wang, Y. Zhang, B. Jiang, X. Xu, and Z. Zhang. Exp.Biol.Med.Maywood. 234(12):1417-1424 (2009)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors

F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom. J.Clin.Oncol. 27(25):4169-4176 (2009)

3 years and 3 months ago

by kanefendt

1

& A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use

(0)

URLDOITeX

Biomarkers of response and resistance to antiangiogenic therapy

R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu, J. S. Loeffler, T. T. Batchelor, and A. G. Sorensen. Nat.Rev.Clin.Oncol. 6(6):327-338 (2009)

3 years and 3 months ago

by kanefendt

1

(0)

URLDOITeX

bookmarks

publications (62)